Introduction

Although the prevalence of PFO is about 25 percent in the general population, this increases up to a third in subjects who have stroke of unknown cause, referred to as cryptogenic stroke, and in young subjects, actually half of strokes are considered as cryptogenic [1]. For quite some time, Obstructive Sleep Apnea Syndrome (OSAS) has been recognized as a condition which increases the risk for stroke in these subjects respect to the general population, especially in young to mid-aged subjects [2,3]. Indeed, the relative risk for developing new vascular problems in untreated OSAS has been estimated in an odds ratio of 2.3 [4]. How frequent the occurrence of stroke in the natural story of OSAS is can furthermore emphasized by data which report that 70-90% of subjects with acute stroke present also OSAS [4-7]. The high prevalence of stroke in OSAS has been correlated in the past principally cardiovascular and hematological factors [8-15]. The most important aspect of all these hematological alterations is characterized by reactive polycythemia in these subjects with an increased likelihood to form microemboli [9,16,17].

This condition of high risk for the occurrence of stroke could be particularly adverse for those subjects with OSAS, who present simultaneously a Patent Foramen Ovale (PFO). Patent Foramen Ovale (PFO) has been found to be the most common interatrial communication [18-23] and it has been shown in previous studies that the prevalence of PFO is significantly higher in subjects with stroke [24-31]. Furthermore, also in subjects with OSAS the prevalence of PFO is significantly higher than in the normal population [32, 33].

The impact of a PFO as risk factor for stroke has been recently additionally stressed, when the diameter of PFO individualized as an independent risk factor for ischemic events (34), especially for recurrent strokes. Because of its valve-like nature, PFO may allow Right to Left Shunting (RLSh) between the right and the left atria during the cardiac cycle as a result of a transient, instantaneous
pressure gradient [35,36] (at rest shunting PFO), and microemboli can, as venous clots, easily reach in this way the arterial circulation, thus favoring cerebral embolism [37].

More frequently RLSH through a PFO can be observed only in the presence of provocative Valsalva-like maneuvers, which increase the right cardiac chamber pressure (provocative shunting PFO). Such a condition of higher right compared to left Atrial pressure can also occur during every day events such as coughing, sport efforts, heavy weight lifting, and breath instrument playing, which are all similar to the provocative Valsalva maneuver. However a study showed that RLSH also occurs in subjects with OSAS during periods of nocturnal apnea, if the apnea length is longer than 17 s [38]. The frequency of these respiratory events in subjects with OSAS is high. In fact, clinical practice shows that among these subjects respiratory events can range from ten to more than 100 apneas per hour.

Based on the hypothesis that the effort of the intra thoracic pressure changes on the right atrium wall due to sleep apneas could contribute in increasing the size of a revealed PFO in subjects with OSAS, a controlled Ventilatory treatment with Continuous Positive Airway Pressure (CPAP), consequently, could help to reduce the magnitude of the RLSH through this PFO, with effects persisting also outside of the periods of nocturnal apnea.

This study investigates, therefore, if a controlled CPAP treatment with high compliance could reduce the magnitude of PFO during wakefulness, reducing by this means the general risk for stroke in these subjects.

Subjects and Methods

The subjects of this study have been enrolled from a previous study in which 78 consecutive subjects with documented medium-severe OSAS have been evaluated for the concomitant presence of a PFO [33]. For all subjects of this sample CPAP treatment was the best eligible therapy. In 21 of 78 screened subjects a PFO has been diagnosed (Figure 1). For the follow-up recording 18 of 21 subjects (4 F and 14 M, mean age: 56 ± 11 years), in whom the presence of an RLSH was demonstrated (Figure 1), was asked to underwent a follow-up visit has been performed after CPAP treatment.

Figure 1: From the group of 78 subjects diagnosed with OSAS, 21 were positive for the comorbidity of PFO. In 18 of these 21 subjects a follow-up visit has been performed after CPAP treatment.

Statistical Analysis

Differences in the rating of the ESS, the BMI, number of microembolic signals during normal respiration and during Valsalva maneuver has been evaluated applying paired t-test procedure. This test has been applied for the whole sample and for the two sub-groups: subjects with already at rest shunting (group A) and subjects with shunting during Valsalva maneuver, provocative shunting, (group B).

Then backward multiple regression analysis has been applied to evaluate the relationship between the magnitude of RLSH reduction on the follow-up respect to the baseline recording (dependent variable) and the following independent variables: CPAP use as months of treatment, daily use (hours) and weekly use (days/week), the CPAP treatment pressure (mbar), age, the condition of atrial fibrillation, the number of HITS at baseline recording.

All computations were performed using the SAS package (software version 6, SAS Inc.) [41].
Results

Though for years, many experts have postulated a cause-and-effect relationship between migraine headaches and PFO [42,43] only one subject referred episodes of migraine without aura. As far as increased risk for strokes regards due to comorbidity of atrial fibrillation, only one subject of the study sample suffered this condition.

Among the 15 subjects who used CPAP treatment, compliance was good with a mean daily use of 6.6 ± 1.5 hours and a meanly weekly use of 6 ± 1 days a week (Table 1).

Despite the small sample size, analysis by paired t-test showed at follow-up respect to baseline significant ESS score decrease for the CPAP users (p<0.0001); see figure 2. In the group of the 3 subjects, who have not used the CPAP device, 2 of 3 subjects showed increased ESS scores at follow-up (Table 2). In addition all CPAP users showed an ESS score lower than 10 (mean ESS score 3 ± 3) vs. non-users (mean ESS score 8 ± 10).

Furthermore at follow-up in the CPAP user group the number of HITS was significantly reduced during Valsalva maneuver, whereas it was not in the non-user group (p<0.01), see table 2 and figure 3. No significant differences could be shown for the number of HITS recorded during physiologic respiration (Table 2). In particular, during Valsalva maneuver in 4 of 15 subjects (27%) no HITS could be recorded at follow-up (100% reduction). A reduction in HITS during Valsalva maneuver at follow-up with respect to the baseline recording of at least 50% has been seen in 11 of 15 subjects (73%). An increase of HITS during Valsalva maneuver at follow-up has been observed only in 1 subject, although the ESS score decreased from 21 at baseline to 0 at follow-up (Table 2).

No statistically significant differences were present for the BMI neither between groups and nor between time (follow-up respect to baseline).

No significant differences have been found for the latency to the microembolic signal and for the BMI.

When multiple regression analysis was applied, the weekly CPAP use (days/week) and the condition of Atrial fibrillation were recognized as these factors, which mainly influence the amount of HTTS at follow-up. In this model the number of days of weekly CPAP use (days/week)

Table 1: Features of the OSAS sample.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (yrs.)</th>
<th>Sex</th>
<th>MwA</th>
<th>AF</th>
<th>CPAP use</th>
<th>months</th>
<th>daily hours</th>
<th>days/ week</th>
<th>CPAP press. (mbar)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>7</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>42</td>
<td>9</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>6</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>5</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>7</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>5</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>33</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>32</td>
<td>7</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>9</td>
<td>64</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>9</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>10</td>
<td>58</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>6</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>44</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>4</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>12</td>
<td>70</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>39</td>
<td>7</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>14</td>
<td>55</td>
<td>M</td>
<td>n</td>
<td>y</td>
<td>y</td>
<td>36</td>
<td>5</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>15</td>
<td>56</td>
<td>F</td>
<td>y</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>16</td>
<td>56</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>31</td>
<td>8</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>17</td>
<td>61</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>18</td>
<td>78</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>30</td>
<td>7</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

Mean (SD) 56 (11)

MwA: migraine without aura; AF: atrial fibrillation; F: female; M: male; y: yes; n: no; SD: Standard Deviation

Table 2: Features of the OSAS sample.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (yrs.)</th>
<th>Sex</th>
<th>MwA</th>
<th>AF</th>
<th>CPAP use</th>
<th>months</th>
<th>daily hours</th>
<th>days/ week</th>
<th>CPAP press. (mbar)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>7</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>42</td>
<td>9</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>6</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>4</td>
<td>49</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>5</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>5</td>
<td>42</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>7</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>6</td>
<td>63</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>45</td>
<td>5</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>33</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>32</td>
<td>7</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>9</td>
<td>64</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>9</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>10</td>
<td>58</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>46</td>
<td>6</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>44</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>44</td>
<td>4</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>12</td>
<td>70</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>39</td>
<td>7</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>14</td>
<td>55</td>
<td>M</td>
<td>n</td>
<td>y</td>
<td>y</td>
<td>36</td>
<td>5</td>
<td>7</td>
<td>15</td>
</tr>
<tr>
<td>15</td>
<td>56</td>
<td>F</td>
<td>y</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>16</td>
<td>56</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>31</td>
<td>8</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>17</td>
<td>61</td>
<td>F</td>
<td>n</td>
<td>n</td>
<td>n</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>18</td>
<td>78</td>
<td>M</td>
<td>n</td>
<td>n</td>
<td>y</td>
<td>30</td>
<td>7</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

Mean (SD) 56 (11)

MwA: migraine without aura; AF: atrial fibrillation; F: female; M: male; y: yes; n: no; SD: Standard Deviation

Note: Highlighted in grey are those subjects, who have not used CPAP during the follow-up period

*Mean value and Standard deviation calculated only for subjects, who used the CPAP
the size of a PFO. In fact, these mechanical factors start to act already at the beginning of an obstructive apnea, where an inspiratory effort against a closed upper airway is present, inducing a decrease in end-inspiratory pleural pressure. This event is followed by swings of increasing and decreasing effects on pleural pressure, influencing directly the interatrial pressure balance and the increase of inspiratory venous return. The consequent right-sided pressure increase will then be at the origin of the RLSH through a PFO. The chronic effect of such a mechanism could also explain the higher prevalence of PFO in subjects with OSAS respect to the control group [32,33].

The well reported high morbidity and mortality in OSAS [2,3,47,48], related particularly to stroke, can be explained by the sequential pathophysiological events, which, occurring during periods of nocturnal obstructive apneas, can compromise the brain CPAP use was negatively and the condition of Atrial fibrillation was positively correlated to the number of HITS recorded at follow-up.

### Discussion

In this study it has been shown for the first time that the daily application of CPAP treatment reduce the magnitude of RLSH in those OSAS subjects, who present concomitantly a PFO, where the non-use do not change the PFO size. In the study sample, the treatment effect of the CPAP device use appears to be related more to the weekly CPAP use (days/week) instead of the daily hours of use. The lack of an impact of the daily use of the CPAP device might however not seen in this sample due to the high daily use (7 ± 2 hours daily).

OSAS subjects with PFO of little size can reveal at follow-up an absolute complete closure of the PFO (Table 2). PFO’s of middle and large size, however show only a partial closure, shifting generally in the next lower class (Table 3, Figure 4). In subjects with PFO of large size and shunting already at rest, the decrease of the magnitude of RLSH at follow-up is not characterized by a shift in the next lower class (Figure 4 and Figure 5).

In previous studies, the diameter of a PFO has been shown to be an independent risk factor for ischemic events, especially recurrent strokes [31,44]. The occurrence of PFO has been associated to genetic factors, especially to mutations of the homeobox gene NKX2-5, but the importance of these factors in sporadic PFO is still open to debate [45,46].

In a previous study [38], it has been shown that nocturnal sleep apnea could act like the Valsalva maneuver in opening of a provocative shunting PFO. This study suggests therefore that the chronic effect of apnea-dependent mechanical factors may influence

![Figure 3: Grading of shunting at follow-up with respect to baseline recording, measured as the number of HITS recorded during Valsalva maneuver. Magnitude of RLSH is classified as 'small' (<10 HITS), 'middle' (10-20 HITS), or 'large' (>20 HITS); large RLSH is divided into 'no curtain pattern' and >20 HITS with curtain pattern.](image)
Citation: Beelke ME. CPAP Treatment Promotes the Closure of a Patent Foramen Ovale in Subjects with Obstructive Sleep Apnea Syndrome - Results from a Pilot Study. SM J Neurol Disord Stroke. 2017; 3(1): 1015.

Chronic CPAP treatment has commonly been seen to reduce the risk for stroke [49-51]. Data from this study suggest, indirectly, that this stroke-protective effect may not only be linked to hematologic and arteriosus pressure features, but also to the ability to reduce the size of a PFO, or absolutely close it. However, to obtain this effect, a high compliance to the CPAP treatment seems to be a prerequisite.

This study shows furthermore, that in subjects with a PFO of big size before treatment and in those subjects with an RLSh already at rest with normal respiration, the decrease of the RLSh at follow-up will be only partially. Considering, that at the moment of diagnosis of PFO in a subject with OSAS it is impossible to preview the magnitude of RLSh decrease due to the CPAP treatment, additional therapeutic approaches as surgical closure of PFO [52] or life-long treatment with anticoagulants or antiplatelet agents should be considered at least, till a follow-up TcD examination do not show a spontaneous PFO closure or a PFO of little size.

Disclosure
This study has been performed at the Center of Sleep Medicine, DISMR, University of Genoa, Italy and the Stroke Unit, Department of Neurosciences and Neurorehabilitation, University of Genoa, Italy. The author is currently not working at these institutions anymore.

Acknowledgment
I thank Silvia Angeli for support during transcranial Doppler assessments and Massimo Del Sette for creative and educational exchange.

References
5. Parra O, Arboix A, Bechich S, Garcia-Eroles L, Montserrat JM, Lopez JA,


35. Strunk BL, Chellin MD, Stulbarg MS, Schiller NB. Right-to-left intralateral shunting through a patent foramen ovale despite normal intracardiac pressures. Am J Cardiol. 1987; 60: 413-415.


